Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Tax Provisions data on file, last reported at $20.5 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 40.87% year-over-year to $20.5 million; the trailing twelve-month figure through Mar 2026 stood at $81.9 million (up 16.07% YoY), and the FY2025 full-year result was $76.0 million, up 22.85% from the prior year.
• Tax Provisions for Q1 2026 stood at $20.5 million, down from $26.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $29.7 million in Q4 2023 and bottomed at -$7.3 million in Q3 2023.
• The 5-year median for Tax Provisions is $13.3 million (2024), against an average of $12.5 million.
• Peak annual rise in Tax Provisions reached 2482.97% in 2023, while the deepest fall reached 322.68% in 2023.
• A 5-year view of Tax Provisions shows it stood at -$1.2 million in 2022, then jumped by 2482.97% to $29.7 million in 2023, then fell by 6.64% to $27.7 million in 2024, then retreated by 6.25% to $26.0 million in 2025, then retreated by 21.08% to $20.5 million in 2026.
• The last three Tax Provisions figures came in at $20.5 million (Q1 2026), $26.0 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.

Peer Comparison